Establishment of monoclonal antibodies against the extracellular domain that block binding of NMO-IgG to AQP4

J Neuroimmunol. 2013 Jul 15;260(1-2):107-16. doi: 10.1016/j.jneuroim.2013.03.003.

Abstract

Neuromyelitis optica is a demyelinating disease characterized by a disease-specific autoantibody designated as NMO-IgG that specifically recognizes aquaporin-4, and the binding of NMO-IgG to AQP4 causes the progress of the disease. Prevention of the binding of NMO-IgG, therefore, may alleviate the disease. Here we have developed monoclonal antibodies against AQP4 with a baculovirus display system in order to obtain high affinity monoclonal antibodies against the extracellular domains of AQP4. Our monoclonal antibodies can block the binding of NMO-IgG in spite of their heterogeneity. Taken together, we propose that our monoclonal antibodies can be applied in clinical therapy for NMO patients.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acid Sequence
  • Animals
  • Antibodies, Monoclonal / immunology*
  • Antibodies, Monoclonal / therapeutic use*
  • Aquaporin 4 / chemistry
  • Aquaporin 4 / genetics
  • Aquaporin 4 / immunology*
  • Autoantibodies / chemistry
  • Autoantibodies / immunology
  • CHO Cells
  • Cricetinae
  • Flow Cytometry
  • Humans
  • Immunoglobulin G / chemistry
  • Immunoglobulin G / immunology*
  • Molecular Sequence Data
  • Neuromyelitis Optica / drug therapy*
  • Neuromyelitis Optica / immunology*
  • Oocytes / cytology
  • Protein Binding / immunology
  • Protein Structure, Tertiary
  • Recombinant Proteins / chemistry
  • Recombinant Proteins / genetics
  • Recombinant Proteins / immunology
  • Xenopus

Substances

  • AQP4 protein, human
  • Antibodies, Monoclonal
  • Aquaporin 4
  • Autoantibodies
  • Immunoglobulin G
  • Recombinant Proteins